SecBot SecBot
8-K ·Filed Nov 5, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 19h ago SEC0001689375-26-000063
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming clinical catalysts: ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, Cohort 2 data in Q1 2027, and Vertex's VX-670 interim results in H2 2026. Cash runway into Q4 2027 provides sufficient funding through these readouts.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

The company highlighted positive safety data from ELEVATE-45-201 Cohort 1 and progress across its DMD clinical pipeline, with multiple data readouts expected through H1 2027.

Key Financial Metrics

Revenue
$905.0K
est $5.9M · -84.7% · -43.9% YoY

Key Facts

  • Net loss of $39.7 million for Q3 2026, compared to $44.1 million in Q3 2025
  • Cash, cash equivalents and marketable securities of $193.0 million as of September 30, 2026
  • Cash runway extended into Q4 2027
  • Collaboration revenue of $0.9 million for Q3 2026, down from $1.6 million in Q3 2025
  • R&D expenses decreased to $32.4 million from $38.4 million year-over-year
  • ELEVATE-45-201 Cohort 1 data met primary safety and tolerability objectives in October 2026
  • FDA granted orphan drug designation for ENTR-601-45 for DMD treatment
  • DMC recommended initiating ELEVATE-44-201 Cohort 3 at highest planned dose (18 mg/kg)
  • Vertex on track to share interim VX-670 GALILEO study results in H2 2026

Financial Impact

Net loss improved by $4.4M YoY; cash burn of $102.7M over nine months; cash runway extended by one quarter vs prior guidance

net losscash positioncash runway

Risk Factors

  • Clinical-stage biotech with no approved products and recurring net losses
  • Cash burn rate of ~$34M per quarter may require future financing
  • Dependence on positive clinical data from multiple ongoing DMD trials

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001689375-26-000063
Document: trda-20261105.htm0001689375-26-000063
Document: 0001689375-26-000063-index-headers.html0001689375-26-000063
Document: 0001689375-26-000063-index.html0001689375-26-000063
Document: 0001689375-26-000063.txt0001689375-26-000063
8-K Data (Synthetic)0001689375-26-000063

Track record

21 reports on TRDA

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  2. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
  3. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
  4. Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
  5. Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
  6. Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
  7. Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
  8. Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
  9. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
  10. Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026